First treatment for sickle cell disease in over 20 years gets NICE recommendation
- Eligible patients in England and Wales will soon have access to Adakveo (crizanlizumab) under a Managed Access Agreement (MAA) to treat vaso-occlusive crises (VOCs)
- By adopting a collaborative approach – including collecting prospective real-world data via the National Haemoglobinopathy Register (NHR) – this decision clears the way for patients with SCD in England to be able to access crizanlizumab
- In addition to collecting valuable real-world evidence which has historically been lacking in this disease area, the partnership agreement between Novartis, NHR, NICE and NHS England aims to identify and address any inequality of uptake, supporting long-term access to treatment and helping to make the UK a centre of excellence for SCD care
Click here to learn more.
SVMPharma is an innovative strategic consultancy, specialising in Real-World Evidence (RWE) for the pharmaceutical industry. SVMPharma generates RWE within UK and Europe through bespoke online Real-World Treatment Evaluators, leading to successful health technology appraisal (HTA) submissions. Clinical trial programmes do not reflect real-world clinical practice and outcomes, RWE supplements and enhances clinical datasets. SVMPharma’s specialist teams focus on delivering the outcomes that matter to your brand.